The preclinical development of T-cell therapies will be managed by Moonlight Bio. Credit: murat photographer/Shutterstock.

Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for challenging cancers.

The partnership integrates Leveragen’s Singularity Sapiens Mouse platform with the T-cell engineering expertise of Moonlight Bio, aiming to improve the efficacy, persistence and functionality of the therapies, particularly for solid tumours.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Leveragen will take charge of discovering fully human single-domain antibodies against therapeutic targets and the preclinical development of the T-cell therapies will be managed by Moonlight Bio.

Moonlight Bio chief scientific officer Jordan Jarjour stated: “At Moonlight Bio, we are dedicated to delivering T-cell therapies that break through barriers obstructing successful outcomes in solid tumours – the vast majority of the global cancer disease burden.

“Leveragen’s Singularity Sapiens Mouse platform is a powerful tool for generating fully human single-domain antibodies with properties that could optimally translate into advanced T-cell therapies, particularly when combined with the tools and technologies that the Moonlight Bio team is advancing.”

The Singularity Sapiens Mouse platform is engineered to produce chain-only antibodies derived from the entire human VH repertoire, incorporated directly into the mouse genome.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It optimises the development of B cells and produces immune responses.

This speeds up the discovery of therapeutic modalities such as messenger ribonucleic acid-based treatments, antibody-drug conjugates, the chimeric antigen receptor-T and bispecifics.

Leveragen founder and CEO Weisheng Chen stated: “Through this partnership with Moonlight Bio, we are combining our state-of-the-art antibody discovery platform with their advanced cell engineering capabilities to develop T cell therapies that have the potential to make a meaningful difference for patients.”

Based in Seattle, Washington, Moonlight Bio aims to develop potency-enhanced T-cell therapies, offering new hope to cancer patients.

In July 2024, Leveragen made a research, option and licence agreement with Moderna to advance the development of various therapeutics.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.